Navigation Links
HDS International Comments on Front-end Carbon Sequestration Technologies
Date:8/19/2011

asing the carbon dioxide and making it available to growing algae only as its needed, on demand.  We accomplish this through our proprietary technologies, which can be used to manage the growth of any biological system.  

"While HDS International is commonly known as an industrial, ocean-based algae biomass production company, our unique carbon fixation technologies provide us with an incremental market opportunity inaccessible to many of our competitors," said Tassos D. Recachinas, HDS International's CEO.  "Holding enabling front-end carbon capture technologies in-house provides us with significant competitive advantages and the ability to directly partner with industrial complexes to reduce their emissions for use in our algae biomass production operations.  The result is the only integrated open-ocean algae production system that can also meaningfully reduce carbon emissions."

The Company is continuing discussions with potential project partners and other vendors within the Back Bay territory, include large carbon emitters.  Given Back Bay's location in Canada—a ratified member of the Kyoto Protocol implementing regulations for carbon dioxide emission caps—the Company expects its integrated carbon capture and industrial, ocean-based algae biomass production projects developed within the Back Bay region to ultimately generate revenues from, among other things, the sale of renewable algae oil and residual biomass, as well as from the generation of carbon reduction credits.  

About HDS International Corp.

HDS International Corp. (OTCQB:  HDSI), based in Providence, RI, is a green technology company providing carbon capture and sequestration solutions, as well as industrial, all natural ocean-based algae farming solutions for the production of renewable, sustainable, and economically viable biofuels, bioproducts, and carbon elimination. Our licensed technologies provide us with an attractive
'/>"/>

SOURCE HDS International Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)
2. Dyadic International Reports 2011 Second Quarter Financial Results
3. International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices
4. Dyadic International Announces Date of Second Quarter 2011 Financial Results Release and Conference Call
5. Roka Bioscience Participates in the International Association for Food Protection Conference
6. Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO® in Secondary Progressive Multiple Sclerosis
7. NAFG Announces Expanded International Surrogacy and Egg Donation Program
8. New Thriller Exposes International Bioterrorism Plot that Leaves the Human Race on the Brink of Certain Disaster
9. Cord Blood America CEO Matthew Schissler Interviewed on International Successes
10. International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility
11. Fiberstar Posts Strong Second Quarter Operating Results on Continued Rising International Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and SHANGHAI , Aug. 31, ... company developing next-generation antibiotics, today announced positive top-line ... for its lead drug candidate MRX-I. MRX-I is ... bacteria such as MRSA and VRE, while offering ... therapeutic option than currently available oxazolidinone agents. ...
(Date:8/31/2015)... CAESAREA, Israel , Aug. 31, 2015 /PRNewswire/ ... the Dario™ Diabetes Management Solution, today announced it ... $2.5 million. Funds will be used to support ... of the Dario, a mobile, cloud-based, diabetes management ... a stylish, ,all-in-one, pocket-sized, blood glucose monitoring device, ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... as a high priority in the drug development approval process. Thus, innovator companies ... This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple educational ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive ... commercially available new FDA approved system in the last 14 years, and the only ... Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and ...
Breaking Biology Technology:MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... Brain Metastases, PALO ALTO, Calif., Sept. 2 ... radiosurgery treatments for,multiple brain metastases using new RapidArc ... ). The MIMA Cancer Center in Melbourne,Florida and ... able to treat brain metastases more quickly and ...
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
Cached Biology Technology:Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 4BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... 2015 The wearable technology market has ... and healthy. However, wearable technology has the potential ... help improve diagnostic capabilities and therapeutic outcomes. Today, ... Wearable Technologies Conference 2015 , where Barrett ... in healthcare.    "Over the past ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... Hole Research Center are analyzing the surprising results of the ... rainforest. , From January 2000 to July 2004, rainfall was ... of the Tapajós National Forest, in Brazil. A total of ... by 6' clear plastic panels suspended 3 to 12 feet ...
... Affymetrix Inc. (Nasdaq: AFFX - News) and Karolinska ... a strategic alliance designed to improve healthcare by ... tools for better diagnosis, prognosis, and treatment. , ... genetic analyses and measurement of gene expression in ...
... have discovered an important chemical in the brain's ... symptoms of opioid drugs like morphine and heroin. ... chemical--called a transporter--could relieve some of the early ... shaking, and jumpiness. Such drugs could become part ...
Cached Biology News:World's largest rainforest drying experiment completes first phase 2World's largest rainforest drying experiment completes first phase 3Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 2Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance 3Key Trigger Of Opioid Withdrawal Symptoms Found 2